Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis.

ABSTRACT: Rarity of light-chain amyloidosis (AL) makes randomized studies challenging. We pooled three phase II studies of immunomodulatory drugs (IMiDs) to update survival, toxicity, and assess new response/progression criteria. Studies included were lenalidomide-dexamethasone (Len-Dex) (n = 37; years: 2004-2006), cyclophosphamide-Len-Dex (n = 35; years: 2007-2008), and pomalidomide-Dex (n = 29; years: 2008-2010) trial. Primary endpoint was hematologic response. Overall survival (OS) was calculated from registration to death and progression-free survival (PFS) was calculated from registration to progression or death. Hematologic, cardiac, and renal response/progression was assessed using the modern criteria. Analysis included 101 patients, with a median age of 65 years, 61% male, 37 newly diagnosed

SUBMITTER: Warsame R 

PROVIDER: S-EPMC6949262 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature